Professional background

Dr Weston graduated from the University of Sheffield Medical School in 2008. He undertook postgraduate general medical training in London, at Charing Cross and Ealing Hospitals (MRCP 2011), and specialist neurology training at St George’s Hospital, the Royal London Hospital, and the National Hospital for Neurology and Neurosurgery. He was awarded a PhD by the UCL Queen Square Institute of Neurology in 2018 for his research into markers of early diagnosis and disease tracking in Alzheimer’s disease.

He is now an MRC clinician scientist and honorary consultant neurologist at the National Hospital for Neurology and Neurosurgery.

Dr Weston runs a specialist cognitive disorders clinic where he has a particular interest in young onset and genetic dementias, and a fortnightly general neurology clinic. 

Research interests

Dr Weston’s research focuses on the use of advanced neuroimaging techniques combined with cutting-edge blood and digital biomarkers to detect and characterise early changes in Alzheimer’s disease and enable earlier, more reliable diagnosis. He has a particular interest in young onset and genetic forms of Alzheimer’s and co-leads UCL’s familial Alzheimer’s disease cohort study.

He has research funding from the Wellcome Trust and the National Institute of Health (NIH) and is a UK Dementia Research Institute Emerging Leader. He is also the National Institute of Health Research (NIHR) Dementia Specialty co-lead for North London.


•    Weston PSJ, Coath W, Harris MJ, Malone IB, Dickson J, Aigbirhio FI, Cash DM, Hui Zhang, Schott JM. Cortical tau is associated with microstructural imaging biomarkers of neurite density and dendritic complexity in Alzheimer’s disease. Alzheimer’s & Dementia. 2023; 19(6).

•    O’Connor A, Cash DM, Poole T, Markiewicz PJ, Frase MR, Malone IB, Jiao J, Weston PSJ, Flore S, Hornbeck R, Mcdade, E, Scholl M, Gordon BA, Bateman RJ, Benzinger TLS, Fox NC. Tau accumulation in autosomal dominant Alzheimer’s disease: a longitudinal [18F]flortaucipir study. Alzheimer’s Research & Therapy. 2023.

•    O'Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston SJ, Heslegrave AJ, Ryan NS, Barker S, Polke JM, Blennow K, Zetterberg H, Fox NC. Plasma GFAP in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. J Neurol Neurosurg Psychiatry 2023; 94(1)

•    O'Connor A, Pannee J, Poole T, Arber C, Portelius E, Swift IJ,  Heslegrave AJ, Abel E,  Willumsen N,  Rice H, Weston PSJ,  Ryan NS,  Polke JM,  Nicholas JM,  Mead S, Wray S,  Chávez-Gutiérrez L,  Frost C,  Blennow K,  Zetterberg H, Fox NC. Plasma amyloid-β ratios in autosomal dominant Alzheimer’s disease: the influence of genotype. Brain. 2021; 144(10).

•    Lu K, Nicholas JM, Weston PSJ, Stout JC, O’Regan AM James S-N, Buchanan SM, Lane CA, Parker TD, Keuss SE, Keshavan A, Murray-Smith H, Cash DM, Sudre CH, Malone IB, Coath W, Wong A, Richards M Henley SMD, Fox NC, Schott JM, Crutch SJ. Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer’s disease. Brain Communications. 2021; 3(1).

•    Weston PSJ, Poole T, Nicholas JM, Toussaint N Simpson IJA, Modat M, Ryan RS Liang Y, Rossor MN Schott JM Ourselin S, Zhang H Fox NC. Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer’s disease. Alzheimer’s Research & Therapy. 2020; 12(112).

•    O’Connor A, Weston PSJ, Pavisic IM, Ryan NS,  Collins JD, Lu K, Crutch SJC,  Alexander DC,  Fox NC  Oxtoby NP. Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. Alzheimer's Research & Therapy. 2020; 12(126).

•    O’Connor A, Karikari TK, Poole T, Ashton NJ, Rodriguez JL, Khatun A, Swift I, Heslegrave AJ, Abel E,  Chung E,  Weston PSJ,  Pavisic IM,  Ryan NS,  Barker SB,  Rossor MN, Polke JM,  Frost C,  Mead S,  Blennow K,  Zetterberg H Fox NC. Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry. 2020; 26.

•    Convery RS, Jiao J, Clarke MTM, Moore KM, Koriath CAM, Woollacott IOC, Weston PSJ, Gunn R, Rabiner I, Cash DM, Rossor MN, Warren JD, Fox NC, Ourselin S, Bocchetta M, Rohrer JD. Longitudinal (18F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. J Neurol Neurosurg Psychiatry. 2020; 91(1).

•    Weston PSJ, Poole T, O'Connor A, Heslegrave A, Ryan NS, Liang Y, Druyeh R, Mead S, Blennow K, Schott JM, Frost CM, Zetterberg H, Fox NC. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimer's Research & Therapy. 2019; 11(1).

•    Weston PSJ, Henley SMD, Liang Y, Nicholas JM, Ryan NS, Macpherson K, Donnachie E, Schott JM, Rossor MN, Crutch SJ, Butler CR, Zeman AZ, Fox NC. Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer’s disease: A cross-sectional study. Lancet Neurology. 2018; 17(2).

•    Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Druyeh R, Malone IB, Ahsan RL, Pemberton H, Klimova J, Mead S, Blennow K, Rossor MN, Schott JM, Zetterberg H, Fox NC. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017; 89(21).

•    Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, Adamson G, Kenny J, Beck J, Chavez-Gutierrez L, de Strooper B, Revesz T, Holton J, Mead S, Rossor MN, Fox, NC. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurology. 2016; 15(13).

•    Weston PSJ, Nicholas JM, Lehmann M, Ryan NS, Liang Y, Macpherson K, Modat M, Rossor MN, Schott JM, Ourselin S, Fox NC. Presymptomatic cortical thinning in familial Alzheimer’s disease: a longitudinal MRI study. Neurology. 2016; 87(19).

•    Weston PSJ, Paterson RW, Dickson J, Barnes A, Bomanji JB, Kayani I, Lunn, MP, Mummery CJ, Warren, JD, Rossor MN, Fox NC, Zetterberg H, Schott, JM. Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid? Journal of Alzheimer’s Disease. 2016; 45(4).

•    Weston PSJ, Paterson RW, Modat M, Burgos N, Cardoso MJ, Magdalinou N, Lehmann M, Dickson JC, Barnes A, Bomanji JB, Kayani I, Cash DM, Ourselin S, Toombs J, Lunn MP, Mummery CJ, Warren JD, Rossor MN, Fox NC, Zetterberg H, Schott JM. Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer’s & Dementia: DADM. 2015; 1(4).

•    Weston PSJ, Simpson IJA, Ryan NS, Ourselin S, Fox NC. Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration. Alzheimer’s Research & Therapy. 2015; 7(1).

•    Weston PSJ, Hunter MD, Wilkinson ID and Woodruff PW. Discrimination of voice gender in the human auditory cortex. Neuroimage. 2015;105.